# US 2009/0270508 A1 · GluR2 receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270508 A1
- Document ID: US20090270508A1
- Status: Published application
- Kind: A1
- Application number: 12/322,274
- Filed: 2009-01-30
- Published: 2009-10-29
- Earliest claimed: 2007-02-23
- Inventors: James Eric Gouaux; Langzhou Song; Yuli Xie; Donald W. Landry
- Web page: https://patentgrep.com/patent/US20090270508A1

## CPC

- C07C 311/03: having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A61P 25/24: Antidepressants
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides for compositions and methods for modulating the GluR2 receptor. It is based, at least in part, on the discovery, by X-ray crystallography, that a known GluR2 agonist binds to the receptor in two different orientations, thereby diminishing its potency. The present invention provides for structural alternatives in which alternative binding possibilities are substantially eliminated.

## Claims

### Claim 1

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound or a pharmaceutically acceptable salt thereof having the structure of formula 1:
R1—R2R3R4—R5
where R1 and R5 are the same and may be alkylaminosulfonyl, alkylaminosulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylaminocarbonyl, alkylaminocarbonylalkyl, alkylaminocarboxy, alkylaminocarboxyalkyl;
where R2 and R4 are preferably, but not necessarily, the same, and are ring structures, optionally substituted, which may be aryl, cycloalkyl, or heterocyclyl; and
where R3 may be a bond between R2 and R4 which either is shared by or joins the two rings without being shared in the rings themselves.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 wherein R2, R3, R4 is a naphthyl group.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 wherein R2, R3, R4 is a bi-aryl group.

### Claim 4

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound or a pharmaceutically acceptable salt thereof having the structure of formula 2:
where R6 and R7 are the same or different and may be alkylaminosulfonyl, alkylaminosulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylaminocarbonyl, alkylaminocarbonylalkyl, alkylaminocarboxy, alkylaminocarboxyalkyl.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4 wherein R6 and R7 are the same and are both alkylaminosulfonyl groups.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4 wherein R6 and R7 are the same and are both alkylaminosulfonylalkyl groups.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6 wherein the compound has the structure of formula 3:

### Claim 8

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound or a pharmaceutically acceptable salt thereof having the structure of formula 4:
where R8 and R9 are the same and may be alkylaminosulfonyl, alkylaminosulfonylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylaminocarbonyl, alkylaminocarbonylalkyl, alkylaminocarboxy, alkylaminocarboxyalkyl.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8 wherein R8 and R9 are both alkylaminosulfonyl groups.

### Claim 10 (depends on 8)

The pharmaceutical composition of claim 8 wherein R8 and R9 are both alkylaminosulfonylalkyl groups.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 wherein the compound has the structure of formula 5:

### Claim 12 (depends on 8)

The pharmaceutical composition of claim 8 wherein the compound has the structure of formula 6:

### Claim 13 (depends on 4)

The pharmaceutical composition of claim 4 wherein the compound has the structure of formula 7:
where R10 and R13 are the same, or, if they are not, then R11 and R12 are the same, and each of R10, R11, R12, and R13 may be H, methyl, ethyl, propyl, isopropyl or butyl.

### Claim 14 (depends on 1)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 1.

### Claim 15 (depends on 2)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 2.

### Claim 16 (depends on 3)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 3.

### Claim 17 (depends on 4)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 4.

### Claim 18 (depends on 5)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 5.

### Claim 19 (depends on 6)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 6.

### Claim 20 (depends on 7)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 7.

### Claim 21 (depends on 8)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 8.

### Claim 22 (depends on 9)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 9.

### Claim 23 (depends on 10)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 10.

### Claim 24 (depends on 11)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 11.

### Claim 25 (depends on 12)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 12.

### Claim 26 (depends on 13)

A method of treating a disorder selected from the group consisting of anxiety and depression, comprising administering an effective amount of a pharmaceutical composition of claim 13.

### Claim 27 (depends on 1)

Use of a compound of claim 1 for preparing a pharmaceutical for use in treating anxiety or depression.

### Claim 28

The compound N,N′-(2R,2′R)-2,2′-(biphenyl-4,4′-diyl)bis(propane-2,1-diyl)dipropane-2-sulfonamide) or a pharmaceutically acceptable salt thereof.

### Claim 29

The compound N,N′-(2S,2′S)-2,2′-(biphenyl-4,4′-diyl)bis(2-fluoropropane-2,1-diyl)dipropane-2-sulfonamide) or a pharmaceutically acceptable salt thereof.

### Claim 30

The compound N,N′-(2S,2′S)-2,2′-(biphenyl-4,4′-diyl)bis(2-hydroxypropane-2,1-diyl)dipropane-2-sulfonamide or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 28, 29, 30)

A pharmaceutical composition in unit dosage form comprising a compound or pharmaceutically acceptable salt thereof of claim 28, 29 or 30 in combination with a pharmaceutically acceptable carrier.

### Claim 32 (depends on 31)

A method of modulating the GluR2 receptor comprising administering to a human an effective amount of a pharmaceutical composition of claim 31.
